Disclaimer:
This article is published by 2Firsts with the author’s permission. The views expressed are solely those of the author and do not necessarily reflect the views of 2Firsts.
Key Points
•The FDA’s pilot program for four nicotine pouch companies does not change existing PMTA standards, and its impact remains limited to those involved.
•While the FDA may accept category-level data in some areas, brand-specific evidence—especially switching studies—continues to play a critical role.
•Relying solely on post-market surveillance is risky; products may still be denied or pulled after launch, causing significant losses.
•Delaying submission in hopes of regulatory relaxation may backfire—early applicants who submit full evidence could gain a competitive advantage.
•The pilot could raise future expectations: those who apply later may be held to higher data standards than early entrants.
The FDA Nicotine Pouch Pilot — What It Signals, What It Does not, and How Applicants Should Prepare Now
Author(s): Samuel C. Hampsher-Monk (ARAC)
With contribution from Dr. Jessica Zdinak (ARAC)
Last month, the FDA confirmed reports it would expedite reviews of PMTAs for four companies’ Nicotine Pouches. Reporting on transcripts of a CTP meeting, Reuters suggested that FDA was under political pressure to expedite reviews. That might be achieved by exempting nicotine pouch applications from having to provide all the brand-specific data that has been integral to all authorizations to date.
The agency has denied that they are relaxing evidentiary standards, but some industry advocates would like to see a greater emphasis on post-market surveillance coupled with the provision of brand-generic information for some aspects of the PMTA. Some believe that the “homogeneity” of these products might afford nicotine pouch applicants a more straightforward avenue to meet FDA’s standards than is available to applicants from other categories.
The potential of this ‘category’ approach rests on the basis, as FDA stated in Zyn’s TPL, that youth use rates for nicotine pouches as a category remained much lower than for e.g., ENDS. Accordingly, the population-level risk (youth and nonuser initiation) is more readily outweighed by benefits (adults using more risky products switching to or significantly reducing daily use).
Plausibly, relative homogeneity of this product category may increase the FDA’s confidence in its ability to make inferences about a candidate product without SKU-specific data. This is likely a welcome prospect for those frustrated with the length of time CTP has taken to initiate and make decisions on PMTAs. Replacing pre-submission studies with post-market surveillance, for example, would reduce a cost barrier to market entry: Pre-submission studies need to be financed, but post-market surveillance can be funded with sales revenue.
1. Why This Pilot Matters — and What Hasn’t Changed
Faced with apparently encouraging signals from the FDA, it would be easy to over-interpret these events. This is just a pilot – a small one. As of right now, this pilot has no bearing on the regulatory standards for applicant sponsors beyond the four companies involved.
Based on the selection criteria for the pilot program, it is almost certain that these applications contain the brand-specific data that many are hoping to one day be exempt from. The legislative standard, “Appropriate for the Protection of Public Health,” as enshrined in the Tobacco Control Act (TCA), remains, requiring the FDA to consider the population risks and benefits of authorizing new tobacco and nicotine products to market.
What, then, has actually changed? How will the market react? And how should those seeking Marketing Authorizations respond?
2.Risks of Relying on Post-Market Surveillance
Initially, a likely consequence is an influx of applications. If that led to more authorizations, this could increase the visibility of the category, and perhaps improve public misperceptions about relative risk, helping incentivize substitutions away from combustibles in the process.
The price dynamics of a more competitive marketplace could do the same. But lower prices resulting from market competition could increase the product category’s appeal more broadly. If youth use accelerates, FDA will likely implement (or resume) more stringent candidate-product specific data requirements as a prerequisite of authorization.
And, as ever, FDA could also order products with certain characteristics removed from the market. For the applicant, this highlights the importance of fulfilling obligations under post-market surveillance; however, what those obligations will be if the assessment turns more to post-market data collection is unknown.
As a regulatory strategy post-market surveillance is hardly bullet-proof: It may mitigate the severity of harms resulting from the consumption of an authorized product by providing a detection mechanism limiting their replication but does not prevent harm occurring in the first place.
If youth use rates do increase, the FDA would be eager to reverse those, likely prompting a similar response to that seen in the wake of the epidemic in youth vaping between 2017 and 2019. Preempting this eventuality, applicants would do well to demonstrate, via post-market surveillance, that their products are not driving any future increase in youth use.
The submission of a robust marketing plan, including details of measures to restrict youth access, reduce youth appeal, and limit youth exposure to labeling, advertising, and marketing, would also be prudent, and the importance of such was highlighted in the Zyn TPL.
3. Which Studies Might Be Optional — and Which Aren’t
Which, if any, studies might an applicant forego?
The Tobacco Product Perception and Intention (TPPI) study might be one candidate. Demonstrating that non-users do not intend to use a candidate product would be valuable to an APPH assessment; however, unless perceptions differ between brands (and in ARAC’s experience conducting these studies with a variety of product categories, including pouches, they largely do not), this might be shown with brand generic data.
Still, the emphasis on post-market surveillance creates a potential risk for applicants. If manufacturers have their products pulled by the FDA after having gone to market, they will not see a return on investment for all the associated costs, in fact the costs for removing all products from the market could be substantial.
4.Why Acting Now May Be Safer Than Waiting
Of course, it’s possible that, once on the market, the FDA does not see reason to order the removal of any brand. Again, ARAC’s experience suggests that at this time, adult non-users disinterest in nicotine pouches is common across brands.
However, that is not true for other studies.
For example, unlike TPPIs, switching studies involving product use tend to produce more heterogenous results between different brands and SKUs. It’s also important to note that Switching Studies/Data is reviewed upon Epidemiological division of CTP, as referenced in TPL summaries and our experience with FDA.
Taking the transcripts at face-value, it is clear that any shift in application standards (not requiring certain studies) will apply to the TPPI study and not behavioral studies such as Switching Studies. Based on CTP TPLs, there are clear distinctions between what data is included in social science reviewer summaries versus epidemiological reviewers.
Factoring in the possibility that conducting a switching study now may, itself, expedite review and a subsequent MGO, and the fact that changes to the evidentiary standards beyond the pilot are uncertain, the equation tips further in favor of acting now since delaying market entry for any reason risks market share and sales.
Consider also the fact that any rapid or uneven adoption of the standards entailed in the pilot program are likely to be litigated. That, again, delays the point at which applicants could benefit.
Ostensibly, the pilot is about expediting reviews. But if nicotine pouch applications surge as a result of the announcement, the resulting burden could off-set any increase in reviewing capacity that CTP gains from streamlining. Submitting now, with all the evidence that the FDA has communicated it typically expects, could save applicants a long and costly wait, or even worse – a Marketing Denial Order (MDO).
That wait is important for another reason too. In the press release accompanying the denial of Blu, FDA cited their previous authorization of similar products with better switching data as a justification for the denial.
That suggests that the benchmark for marketing authorization may get higher over time, with late-commers having to out-perform those authorized to date. If there is going to be a wave of new pouch applicants, those at the front will have much to gain.
5. Understanding FDA’s Archetype Approach to Pouches
What advice, then, is there for applicants?
Avoiding the temptation to over-interpret these developments would be a good place to start. There is nothing in the reports to suggest that any new review program would extend beyond nicotine pouches, or even beyond the 4 companies and their associated candidate products selected for this program.
And even for this product category, the FDA is still required to make an APPH determination in order to authorize marketing of such products.
It would also be a mistake to assume that all pouch products will be fast-tracked, even if any are. The program seems to be premised on the idea that nicotine pouches are sufficiently homogenous as a product category that the agency might make informed decisions about a brand or SKU based on generic category-level data, along with SKU-specific manufacturing/marketing, toxicology, and abuse liability.
That suggests that FDA has an archetype, or a range of archetypical characteristics and features, in mind. But the details have not been articulated.
If the ‘essential data’ required under the Pilot’s standard lead the FDA to conclude that an applicant’s product is sufficiently different from the archetype, whether due to nicotine strength, flavor profile, marketing decisions, or pouch type (wet-dry etc.) etc., FDA might still conclude that applicants need to submit candidate product-specific data for all PMTA scientific areas.
It is simply not clear how much deviation from archetypical standards or how much increase in youth use, would be acceptable or unacceptable, respectively, before an applicant would need to revert to the traditional approach to demonstrating APPH standard.
6.Strategic Takeaways for PMTA Applicants
The FDA’s announcement is an encouraging sign that it is taking pragmatic steps to expedite the review process underpinning the authorization of nicotine pouch products. The FDA seems to be focused on two key components of the Reagan-Udall review – to increase communications and transparency with applicants, and to speed up application reviews and decisions.
However, the practical implications for applicants beyond those participating in the current pilot are unclear. ARAC is closely tracking these developments and helping our clients strategize the best path forward. ARAC’s expertise bridges behavioral science & regulatory science — helping applicants turn compliance into a competitive advantage.
About Applied Research and Analysis Company (ARAC):
Applied Research and Analysis Company (ARAC) is a premier U.S.-based behavioral science research firm with global reach, specializing in regulatory science and real-world impact. ARAC designs and delivers high-quality, defensible studies that support regulatory submissions — including PMTAs, MRTPAs, and SEs — driving product development decisions across the nicotine and tobacco space.
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort studies, and Tobacco Product Perceptions and Intentions (TPPI).
ARAC’s cross-functional team of scientists, clinicians, strategists, and regulatory experts collaborate with clients from concept to clearance — supporting innovation, advancing harm reduction, and building confidence in regulatory engagement. From global product development to post-market surveillance, ARAC delivers science that shapes policy, informs consumers, and helps manufacturers succeed in complex regulatory landscapes.
Learn more at ARACscience.com
